Last $25.97 USD
Change Today -1.41 / -5.15%
Volume 6.1M
EXAS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 5:20 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

exact sciences corp (EXAS) Snapshot

Open
$27.51
Previous Close
$27.38
Day High
$28.69
Day Low
$25.66
52 Week High
12/10/14 - $29.97
52 Week Low
05/8/14 - $10.69
Market Cap
2.3B
Average Volume 10 Days
2.0M
EPS TTM
$-1.03
Shares Outstanding
88.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EXACT SCIENCES CORP (EXAS)

exact sciences corp (EXAS) Related Bloomberg News

View More Bloomberg News

exact sciences corp (EXAS) Related Businessweek News

No Related Businessweek News Found

exact sciences corp (EXAS) Details

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company’s stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

102 Employees
Last Reported Date: 02/28/14
Founded in 1995

exact sciences corp (EXAS) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $738.5K
Principal Financial Officer and Senior Vice P...
Total Annual Compensation: $84.6K
Chief Operating Officer, Senior Vice Presiden...
Total Annual Compensation: $508.3K
Chief Science Officer and Senior Vice Preside...
Total Annual Compensation: $474.3K
Compensation as of Fiscal Year 2013.

exact sciences corp (EXAS) Key Developments

Exact Sciences Corporation Announces Cologuard

Exact Sciences Corporation announced that Mercy Hospital St. Louis will now offer Cologuard(R), the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Colorectal cancer is the second-leading cancer related cause of death in the United States and is often the most preventable. However, due to the lack of patient compliance with current screening options, it's the least prevented cancer. Cologuard analyzes a person's stool to detect both altered DNA and blood known to be associated with colorectal cancer and precancer. It has been proven to find 92% of colorectal cancers in average risk patients with 87% specificity using a single sample. Unlike many other screening options, Cologuard does not require medication, dietary restrictions or bowel preparation prior to taking the test. Mercy is the first hospital in the St. Louis area to make this new option available. Most colorectal cancers develop slowly over several years. Before cancer develops, a polyp--a non-cancerous growth - usually appears on the inner lining of the colon or rectum. The identification and removal of these polyps, through routine screenings, can effectively prevent colorectal cancer. For those whose cancer is detected at an early stage, the five-year survival rate can be greater than 90%, making routine screening critical. Unfortunately, 23 million Americans aged 50 and over do not get screened as recommended.

American Cancer Society Includes Exact Sciences' Cologuard in Colorectal Cancer Prevention and Early Detection Guidelines

Exact Sciences Corp. announced that the American Cancer Society's Colorectal Cancer Prevention and Early Detection national guidelines for colorectal cancer screening now reflect the commercial availability of Cologuard, the company's noninvasive stool DNA colorectal cancer screening test. The American Cancer Society (ACS) guidelines include Cologuard in a recommended list of screening options for colorectal cancer. ACS guidelines also reflect the Centers for Medicare and Medicaid Services assessment that Cologuard be performed every three years for patients 50 and older who do not have symptoms of colorectal cancer and who do not have an increased risk of colorectal cancer. Medicare covers Cologuard for individuals age 50-85 fitting these criteria once every three years at no cost to patients. Updated information on the ACS website also describes the process by which patients can access Cologuard, including information about collecting and sending samples to the lab for testing and the latest information on Medicare coverage. Available by prescription only, Cologuard is the first and only FDA approved noninvasive stool DNA screening test for colorectal cancer. Cologuard offers people 50 years and older who are at average risk for colorectal cancer an easy to use screening test which they can do in the privacy of their own home. Cologuard is designed to detect DNA alterations and blood released from cancer and precancerous colon lesions and has been proven to find 92% of colorectal cancers in average risk patients with 87% specificity using only a single sample. Cologuard does not require medication, dietary restrictions or bowel preparation prior to taking the test.

Exact Sciences Corporation Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 01:00 PM

Exact Sciences Corporation Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 01:00 PM. Venue: The Westin Grand Central, New York, New York, United States. Speakers: Maneesh K. Arora, Chief Operating Officer, Senior Vice President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXAS:US $25.97 USD -1.41

EXAS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $2.44 USD +0.01
Curis Inc $1.17 USD +0.02
Delcath Systems Inc $1.38 USD -0.05
MELA Sciences Inc $1.30 USD -0.01
Navidea Biopharmaceuticals Inc $1.79 USD +0.05
View Industry Companies
 

Industry Analysis

EXAS

Industry Average

Valuation EXAS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,622.7x
Price/Book 10.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,488.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXACT SCIENCES CORP, please visit www.exactsciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.